A Phase 4 interventional study of Placebo (matching) and Beta-blockers in Heart Failure, HFpEF and HFpEF - Heart Failure With Preserved Ejection Fraction, sponsored by Weill Medical College of Cornell University. Enrolling by invitation at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies testing Beta blockers in Heart Failure — 9 open to participants now, 9 under way, none of them phase 3. A drug class: Beta blockers · Heart Failure.
Among the 56 studies testing Beta blockers in Heart Failure, this one is the 11th largest by planned enrollment of the 55 interventional ones that give a count, is one of 2 that started in 2026, is one of 27 in phase 4, and was the 56th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →9 of the 56 studies testing Beta blockers in Heart Failure are open now, in 5 countries. Recruiting first, the newest first:
University of Rochester · Sites in United States
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18+
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18+
Erasmus Medical Center · Sites in Netherlands
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 65+
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 11 · Phase 4 27
First in 1994; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 63 across the 55 interventional studies. Of the 36 that completed or were terminated, 14 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 56 have an industry lead sponsor. The 10 most frequent:
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
13 studies in Heart Failure by Weill Medical College of Cornell University: 5 open now, 5 under way, none of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 13 studies in Heart Failure by Weill Medical College of Cornell University, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 in phase 4, and was the 13th registered.
Weill Medical College of Cornell University’s Heart Failure studies by the year they started, since 2020.
3 of the studies testing Beta blockers in Heart Failure that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05585125Weill Medical College of Cornell UniversityA Preliminary Study for INFORMED | 2027-02 |
| NCT07252310Weill Medical College of Cornell UniversityPilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App) | 2027-02 |
| NCT06793670Università Vita-Salute San RaffaeleLandiolol in Mitral Valve Surgery | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies testing Beta blockers in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Weill Medical College of Cornell University’s 13 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn whether stopping beta-blockers can help older adults with heart failure with preserved ejection fraction (HFpEF) feel better and function better. This study will test whether "deprescribing" or stopping these medications in a careful, guided way can improve symptoms and quality of life.
Participants will be randomly assigned to one of two groups:
Deprescribing group: Beta-blockers are gradually reduced using capsules that contain decreasing doses.
Usual care group: Beta-blockers are continued at the usual dose in look-alike capsules.
All participants will:
This study does not involve any experimental medication. Participants active involvement in the study will last approximately 4 months. During these 4 months they will have 8 scheduled telephone visits.
The criteria were revised on the registry on Oct 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence of HF, defined by at least one of the following:
Exclusion Criteria:
Compelling guideline indication for ß-blocker:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will have their beta-blocker replaced with pills that have decreasing amounts of beta-blocker until they are completely off their medicine and taking placebo pills.
Drug: Placebo (matching)
Participants will continue their beta-blocker at their usual dose in capsules that look identical to those used for the deprescribe arm.
Drug: Beta-blockers
Beta-blocker dosage will be reduced over the course of 4 weeks until the participant is completely off of beta-blocker and transitioned to matching placebo capsules.
Also known as: Deprescribing
Participants will continue their pre-enrollment beta-blocker at the same dose. The beta-blocker agent may include atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate. Medication will be provided in matching capsules to maintain blinding.
Also known as: Atenolol, Bisoprolol, Carvedilol, Metoprolol succinate, Metoprolol tartrate
The Hierarchical Composite Endpoint
The primary outcome is net benefit, assessed using a hierarchical composite of four patient-centered outcomes: (1) time to death from any cause, (2) time to all-cause hospitalization, (3) ≥ 5-point difference of KCCQ-12 OSS change from baseline, and (4) ≥ 3-point difference in PROMIS Depression T-score change from baseline
Time frame: From baseline (randomization) to 120 days after study drug initiation
The change from baseline in patient-reported physical health, as measured by the KCCQ-12
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a heart failure-specific health status survey. The 12-item questionnaire asks participants to rate their agreement with a series of statements using a six-point Likert scale, ranging from "completely disagree" (0) to "completely agree" (5). Item responses are summed to generate a total score ranging from 0 to 100, with higher scores indicating better health status.
Time frame: From baseline (randomization) to 120 days after study drug initiation
The change in patient-reported mental health, as measured by the PROMIS Depression scale
The PROMIS Depression scale is a validated 4-item patient-reported measure developed by the NIH, with high reliability and responsiveness in older adults. The 4-item questionnaire asks participants to rate their agreement with a series of statements using a six-point Likert scale, ranging from "never" (0) to "always" (5). Item responses are summed to generate a raw score ranging from 4 to 20, which is then converted to a standardized T-score using PROMIS scoring guidelines. Higher scores indicate greater depressive symptom severity.
Time frame: From baseline (randomization) to 120 days after study drug initiation
Plan to share: Yes — Data collected for this study will be shared only after the publication of findings addressing the study's specific aims. Data generated under this project will be managed in accordance with the policies of Weill Cornell Medicine (WCM) and the NIH, including the NIH Data Sharing Policy and Implementation Guidance. After publication of our main findings, data will be made available for secondary analyses. External researchers may request access to the data by submitting a written proposal outlining the hypotheses to be tested. All data will be de-identified to protect participant confidentiality.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: The data will be shared after we have published the primary results of this study. There is no end date to access the data from the research project.
Access criteria: Researchers granted access to the data will be required to use it solely for research purposes, ensuring that no individual participants are identifiable. They must also implement appropriate security measures, such as using password-protected servers and files, to safeguard the data. Upon completion of the analyses, the data must be returned or destroyed. Released datasets will be subject to stringent safeguards to ensure compliance with the Health Insurance Portability and Accountability Act (HIPAA). Additionally, a data-sharing agreement will be required, specifying that the data is used exclusively for research purposes and that no participants are identifiable. Any additional approvals required by participating institutions, including KPNC, will be obtained. A data management plan will also be necessary to ensure the continued security and confidentiality of the data, as well as to outline the process for returning or destroying the data once the analysis is complete.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Apr 2029, 38 months after the start.
Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 38 months is above that.
Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beta blockers
Weill Medical College of Cornell University →